152 / 1498
Durability of Clinical Responses with
90
Y Ibritumomab Tiuxetan
Patients Progression-F
ree, %
TTP, months
100
90
80
70
60
50
40
30
20
10
0
0
10
20
30
40
50
60
70
80
Median TTP = 29.3 months
Wiseman GA, et al.
Cancer Biother Radiopharm
. 2005;20(2):185-188.
Time to progression in patients with long-term responses (TTP ≥12
months) to
90
Y ibritumomab tiuxetan (n = 78)